{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:34:16Z","timestamp":1792154056449,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jhep.2019.10.010","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T19:47:55Z","timestamp":1571860075000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-2622","authenticated-orcid":false,"given":"Gregory J.","family":"Dore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-0186","authenticated-orcid":false,"given":"Marianne","family":"Martinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-1179","authenticated-orcid":false,"given":"Andrew J.","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"M\u00fcllhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3116-0747","authenticated-orcid":false,"given":"Michael","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hezode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard Estivill","family":"Mercade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Kho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Petoumenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0480-1203","authenticated-orcid":false,"given":"Philippa","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Tatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Gabriela Pires","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jhep.2019.10.010_b0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"The Polaris Observatory","year":"2017","journal-title":"Lancet Gastro Hepatol"},{"key":"10.1016\/j.jhep.2019.10.010_b0010","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.010_b0015","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.10.010_b0020","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.010_b0025","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.010_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvh.12253","article-title":"Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward)","volume":"21","author":"Dore","year":"2014","journal-title":"J Viral Hepatitis"},{"key":"10.1016\/j.jhep.2019.10.010_b0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1478-3231.2010.02411.x","article-title":"New direct-acting antivirals' combination for the treatment of chronic hepatitis C","volume":"31","author":"Asselah","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.10.010_b0040","unstructured":"WHO. Global Hepatitis Report 2017. Geneva, 2017."},{"key":"10.1016\/j.jhep.2019.10.010_b0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12\u202fweeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.010_b0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.10.010_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131437","article-title":"The influence of hepatitis C virus genetic region on phylogenetic clustering analysis","volume":"10","author":"Lamoury","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2019.10.010_b0060","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3109\/23744235.2015.1028097","article-title":"Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden","volume":"47","author":"Lindstrom","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.jhep.2019.10.010_b0065","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/JCM.06689-11","article-title":"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","volume":"50","author":"Woods","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2019.10.010_b0070","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.10.010_b0075","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.10.010_b0080","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.010_b0085","unstructured":"ICH Expert Working Group. ICH harmonised tripartite guidline: Statistical principles for clinical trials E9, 1998."},{"key":"10.1016\/j.jhep.2019.10.010_b0090","unstructured":"Food and Drug Administration. Non-Inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry: U.S. Department of Health and Human Services 2016."},{"key":"10.1016\/j.jhep.2019.10.010_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.10.010_b0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.10.010_b0105","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12072-015-9680-7","article-title":"High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study","volume":"10","author":"Petersen","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2019.10.010_b0110","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1089\/apc.2014.0308","article-title":"Interventions for enhancing adherence to antiretroviral therapy (ART): a systematic review of high quality studies","volume":"29","author":"Mbuagbaw","year":"2015","journal-title":"Aids Patient Care Std"},{"key":"10.1016\/j.jhep.2019.10.010_b0115","first-page":"369","article-title":"The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to Efavirenz-based HAART over 48\u202fweeks: the NOCTE study","volume":"53","author":"Cooper","year":"2010","journal-title":"Jaids-J Acq Imm Def"},{"key":"10.1016\/j.jhep.2019.10.010_b0120","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1468-1293.2008.00618.x","article-title":"Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy","volume":"9","author":"Maitland","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.jhep.2019.10.010_b0125","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/596482","article-title":"Better adherence with once-daily antiretroviral regimens: a meta-analysis","volume":"48","author":"Parienti","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2019.10.010_b0130","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.10.010_b0135","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org (accessed 22-03-2019)."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:38:15Z","timestamp":1759174695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819306129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0168827819306129"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.10.010","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}